Thöny Beat, Blau Nenad
Division of Clinical Chemistry and Biochemistry, University Children's Hospital, Zurich, Switzerland.
Hum Mutat. 2006 Sep;27(9):870-8. doi: 10.1002/humu.20366.
Tetrahydrobiopterin (BH(4)) deficiencies are a highly heterogeneous group of disorders with several hundred patients, and so far a total of 193 different mutant alleles or molecular lesions identified in the GTP cyclohydrolase I (GTPCH), 6-pyruvoyl-tetrahydropterin synthase (PTPS), sepiapterin reductase (SR), carbinolamine-4a-dehydratase (PCD), or dihydropteridine reductase (DHPR) genes. The spectrum of mutations causing a reduction in one of the three biosynthetic (GTPCH, PTPS, and SR) or the two regenerating enzymes (PCD and DHPR) is tabulated and reviewed. Furthermore, current genomic variations or SNPs are also compiled. Mutations in GCH1 are scattered over the entire gene, and only 5 out of 104 mutant alleles, present in a homozygous state, are reported to cause the autosomal recessive form of inheritable hyperphenylalaninemia (HPA) associated with monoamine neurotransmitter deficiency. Almost all other 99 different mutant alleles in GCH1 are observed together with a wild-type allele and cause Dopa-responsive dystonia (DRD, Segawa disease) in a dominant fashion with reduced penetrance. Compound heterozygous or homozygous mutations are spread over the entire genes for PTS with 44 mutant alleles, for PCBD with nine mutant alleles, and for QDPR with 29 mutant alleles. These mutations cause an autosomal recessive inherited form of HPA, mostly accompanied by a deficiency of the neurotransmitters dopamine and serotonin. Lack of sepiapterin reductase activity, an autosomal recessive variant of BH(4) deficiency presenting without HPA, was diagnosed in patients with seven different mutant alleles in the SPR gene in exons 2 or 3 or in intron 2. Details on all mutations presented here are constantly updated in the BIOMDB database (www.bh4.org).
四氢生物蝶呤(BH(4))缺乏症是一组高度异质性的疾病,患者达数百人,迄今为止,在鸟苷三磷酸环化水解酶I(GTPCH)、6-丙酮酰四氢蝶呤合成酶(PTPS)、蝶呤还原酶(SR)、甲醇胺-4a-脱水酶(PCD)或二氢蝶啶还原酶(DHPR)基因中总共鉴定出193种不同的突变等位基因或分子损伤。列出并综述了导致三种生物合成酶(GTPCH、PTPS和SR)之一或两种再生酶(PCD和DHPR)活性降低的突变谱。此外,还汇编了当前的基因组变异或单核苷酸多态性。GCH1基因的突变分散在整个基因中,据报道,104个纯合状态的突变等位基因中只有5个会导致与单胺神经递质缺乏相关的常染色体隐性遗传性高苯丙氨酸血症(HPA)。GCH1基因中几乎所有其他99种不同的突变等位基因都与野生型等位基因一起出现,并以显性方式导致多巴反应性肌张力障碍(DRD,Segawa病),外显率降低。复合杂合或纯合突变分布在整个PTS基因(有44个突变等位基因)、PCBD基因(有9个突变等位基因)和QDPR基因(有29个突变等位基因)中。这些突变导致常染色体隐性遗传性HPA,大多伴有神经递质多巴胺和血清素缺乏。在SPR基因外显子2或3或内含子2中有7种不同突变等位基因的患者被诊断为缺乏蝶呤还原酶活性,这是一种无HPA表现的BH(4)缺乏症的常染色体隐性变异型。此处介绍的所有突变的详细信息在BIOMDB数据库(www.bh4.org)中不断更新。